Dirk Sibbing Shares Phase 3 Study on Dissaggpro for STEMI – Rapid Onset and Fast Offset of Antiplatelet Action!
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”A new drug on the horizon for pre-hospital treatment of STEMI patients
Subcutaneous GPIIb/IIIa – Dissaggpro
Rapid onset and fast offset of antiplatelet action
Phase 3 Study (CeleBrate) of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results as announced by CeleCor Therapeutics
This, for sure, will bring new aspects into the discussions on pretreatment (antiplatelet) for STEMI patients…
Still we are loosing too many patients pre-hospital and before we see them in the cath lab…
Results will be presented as LBCT at AHA 2025 in New Orleans
Arnoud van ‘t Hof, Robert S. Hillman, Jur ten Berg, C. Michael Gibson, M.S., M.D.”
Read the full article here.
Article: Phase 3 Study of Novel Anti-Platelet Drug for Heart Attack Reports Positive Topline Results
Stay updated on all scientific advances in the field with Hemostasis Today.
-
Sep 9, 2026, 11:03Abdul Muqtadir Abbasi: Why Platelets Go Low in ITP?
-
Sep 9, 2026, 10:40Katrina Snow: Non-Invasive Fetal Blood Group Genotyping Is Coming to Ontario
-
Sep 9, 2026, 10:23Kalyan Roy: Could Alzheimer’s-Related Proteins Be Transmitted Through Blood Transfusion?
-
Sep 9, 2026, 07:31Fateema Capery: The State of Hemophilia Care in Mauritius and What Comes Next
-
Sep 9, 2026, 07:11Building a Stronger Future for Hemophilia Care in Bangladesh – World Federation of Hemophilia
-
Sep 9, 2026, 07:05Nael Ismail: Gene and Cell Therapy Are Transforming the Treatment of Human Genetic Diseases
-
Sep 9, 2026, 06:59Suswapna Singh Rawat: The Role of Platelets in Heart Disease and Antiplatelet Therapy
-
Sep 9, 2026, 06:39Chaza Alaji: How Hemophilia Became a Disease of Precision Medicine
-
Sep 9, 2026, 05:52Faheema Hasan: New ASH 2026 Guidelines Redefine Initial and Second-Line ITP Therapy